0119 Broadcast DATE: October 16, 2007 SUBJECT: RTOG Study Terminations-Title Corrections The studies listed below are completed and will be terminated (all study activity and data collection ceased; terminated at your local IRB) as of October 22, 2007. Any data received after this date will be returned. 9901 (Symptom Management) "A PHASE III STUDY TO TEST THE EFFICACY AND SAFETY OF GM-CSF TO REDUCE THE SEVERITY AND DURATION OF MUCOSAL INJURY AND PAIN (MUCOSITIS) ASSOCIATED WITH CURATIVE RADIATION THERAPY IN HEAD AND NECK CANCER PATIENTS" 9913 (Symptom Management) "A PHASE III COMPARISON OF BIAFINE TO DECLARED INSTITUTIONAL PREFERENCE FOR RADIATION INDUCED SKIN TOXICITY IN PATIENTS UNDERGOING RADIATION THERAPY FRO ADVANCED SQUAMOUS CELL CARCINOMAS OF THE HEAD AND NECK." 0119 (Symptom Management) "A RANDOMIZED PHASE II STUDY OF A.M. AND P.M. MELATONIN FOR BRAIN METASTASIS IN RPA CLASS II PATIENTS" 0021 (CNS) "A PHASE II TRIAL OF CONVENTIONAL RADIATION THERAPY PLUS HIGH DOSE TAMOXIFEN FOR THE TREATMENT OF SUPRATENTORIAL GLIOBLASTOMA MULTIFORME (GBM)" 0013 (CNS) "A PHASE II TRIAL OF CONVENTIONAL RADIATION THERAPY FOLLOWED BY INTRATUMORAL BLEOMYCIN DELIVERED USING A REFILLABLE, SUSTAINED RELEASE DEVICE (IND# 46,592) FOR THE TREATMENT OF SUPRATENTORIAL GLIOBLASTOMA" DATE: October 15, 2007 SUBJECT: RTOG Study Terminations The studies listed below are completed and will be terminated (all study activity and data collection ceased; terminated at your local IRB) as of October 22, 2007. Any data received after this date will be returned. 9901 (Symptom Management) "A PHASE III STUDY TO TEST THE EFFICACY AND SAFETY OF GM-CSF TO REDUCE THE SEVERITY AND DURATION OF MUCOSAL INJURY AND PAIN (MUCOSITIS) ASSOCIATED WITH CURATIVE RADIATION THERAPY IN HEAD AND NECK CANCER PATIENTS" 9913 (Symptom Management) "A PHASE III COMPARISON OF BIAFINE TO DECLARED INSTITUTIONAL PREFERENCE FOR RADIATION INDUCED SKIN TOXICITY IN PATIENTS UNDERGOING RADIATION THERAPY FRO ADVANCED SQUAMOUS CELL CARCINOMAS OF THE HEAD AND NECK." 0119 (Symptom Management) "A PHASE II STUDY OF EXTERNAL BEAM RADIATION THERAPY COMBINED WITH PERMANENT SOURCE BRACHYTHERAPY FOR INTERMEDIATE RISK CLINICALLY LOCALIZED ADENOCARCINOMA OF THE PROSTATE" 0021 (CNS) "A RANDOMIZED PHASE II STUDY OF A.M. AND P.M. MELATONIN FOR BRAIN METASTASIS IN RPA CLASS II PATIENTS" 0013 (CNS) "A PHASE II TRIAL OF CONVENTIONAL RADIATION THERAPY FOLLOWED BY INTRATUMORAL BLEOMYCIN DELIVERED USING A REFILLABLE, SUSTAINED RELEASE DEVICE (IND# 46,592) FOR THE TREATMENT OF SUPRATENTORIAL GLIOBLASTOMA" DATE: December 14, 2004 SUBJECT: RTOG 9813, 0215, 0315, 0119 Holiday Drug Ordering and Shipping Schedule (BIOLOGICS) The Holiday Schedule for Biologics, the distributor for the following RTOG studies is listed below: RTOG 9813 RTOG 0215 RTOG 0315 RTOG 0119 ** HOLIDAY REMINDER** Biologics Inc. closed for Christmas and New Year’s Biologics Inc. will honor the Christmas holiday by closing December 24th. We will resume normal business hours Monday, December 27th. We will also be closed on December 31st. We will resume normal business hours Monday, January 3, 2005. ___________________________________________ Please contact Leigh Hancock, Clinical Trials Manager, with any questions regarding shipping times for all RTOG studies. PHONE: 800.850.4306 or 919.546.9810 FAX: 919.546.9816 Happy Holidays! Web registration is available 24/7. Information and instructions are at https://silver1.phila.acr.org/Clinical_RTOG/pgIndex.html